Corticosteroids in spinal trauma: where the controversy stands

Few emergency decisions in spinal trauma generate as much debate as whether to administer high-dose corticosteroids. Methylprednisolone has been studied for decades as a possible treatment for acute spinal cord injury, yet the balance between modest neurological benefit and potentially serious harm remains unsettled. The discussion has moved beyond a simple “give it” or “do not give it” rule: timing, injury pattern, physiological stability, age, comorbidities and local capability all influence the decision.

For Australian clinicians, the issue is especially relevant because trauma care often involves long retrievals, variable access to spinal specialists and substantial differences between metropolitan trauma centres and regional hospitals. A patient injured near Broome, Alice Springs or a remote Queensland property may spend hours in transit before definitive imaging and specialist review. In that setting, a steroid protocol can appear attractive as an early intervention, but its risks must be weighed against the realities of transport, monitoring and delayed surgery.

Why methylprednisolone became part of the spinal trauma debate

The biological rationale is understandable. After the initial mechanical injury to the spinal cord, secondary processes such as inflammation, lipid peroxidation, oedema, excitotoxicity and cell membrane damage may extend neurological loss. Corticosteroids suppress inflammatory activity and may reduce some components of secondary injury. This led to the National Acute Spinal Cord Injury Studies, particularly NASCIS II, which reported a small neurological advantage when high-dose methylprednisolone was started within eight hours of injury.

The protocol was demanding: a bolus followed by a prolonged infusion, with treatment duration influenced by the time from injury. NASCIS III examined 24-hour and 48-hour regimens, especially for patients who received treatment between three and eight hours after trauma. These trials shaped practice internationally, although their methodology, post hoc analyses and clinical significance have been questioned. A few points of motor recovery may be statistically detectable without producing a meaningful change in independence, walking ability or quality of life.

The controversy grew because the intervention is not a benign anti-inflammatory dose. High-dose therapy can worsen hyperglycaemia, gastrointestinal bleeding, wound complications, pneumonia, sepsis and delirium. It may also complicate operative recovery and obscure evolving infection. These concerns are particularly important in older adults, people with diabetes, patients with chest trauma and those who require prolonged ventilation.

What contemporary guidelines actually say

Modern guidance has generally become more cautious rather than uniformly prohibitive. The AO Spine clinical practice guideline has described a 24-hour high-dose methylprednisolone infusion within eight hours as an option that may be offered to adults with acute traumatic spinal cord injury, while advising against a 48-hour infusion. The recommendation is weak because the evidence is low quality and the estimated benefit is small. Treatment after eight hours is generally not supported.

Other professional bodies have taken a more conservative position, advising against routine administration because adverse events may outweigh uncertain neurological gains. This difference is important: “an option” does not mean “standard care”. A clinician who declines steroids after considering the circumstances is not withholding an established neuroprotective treatment. Equally, a carefully selected patient treated within the appropriate window may receive a defensible intervention.

The practical implication is that local protocols should state the limits clearly. Steroids should never delay airway management, spinal motion restriction, haemorrhage control, imaging, reduction of a dislocation or transfer to a trauma service. They should not be used for isolated spinal pain without evidence of cord injury, nor for chronic cord compression, metastatic disease or non-traumatic myelopathy. The proposed indication is acute traumatic spinal cord injury, and even there the decision needs senior clinical oversight.

Timing, injury pattern and patient selection

Time from injury is central to the argument. If treatment is considered, the greatest potential benefit is associated with commencement within eight hours, with no convincing rationale for beginning it after that period. Precisely establishing the injury time can be difficult after a fall, sporting collision or delayed discovery. A patient found unconscious may have been injured hours earlier, making an aggressive protocol inappropriate.

The neurological examination also matters. Steroids should not be treated as a substitute for urgent decompression in a patient with a surgically correctable lesion. A cervical fracture-dislocation, epidural haematoma or ongoing compression requires rapid imaging and specialist management. Incomplete injuries may prompt more discussion because there is potentially useful neurological function to preserve, but the presence of an incomplete injury does not automatically justify treatment.

Patient factors can shift the balance decisively. Severe diabetes, active infection, immunosuppression, gastrointestinal ulceration, frailty and polytrauma increase the likelihood of harm. A younger person with a severe cervical cord injury who reaches a major trauma centre within two hours may present a different risk profile from an older patient with thoracic injury, rib fractures, sepsis risk and an eight-hour retrieval ahead. These distinctions should be documented rather than hidden behind a generic order set.

In Australia, retrieval medicine adds another layer. The Victorian State Trauma System, NSW trauma network and retrieval services supporting the Northern Territory and Western Australia all operate across large geographic areas, but their pathways and available monitoring are not identical. A dose given in a small emergency department may need to be followed by hours of aeromedical transfer. That makes glucose surveillance, infection assessment, pressure-area care and communication with the receiving spinal unit essential.

The harms that influence bedside decisions

Hyperglycaemia is common after major trauma even without steroids. Adding a high-dose infusion can produce marked glucose elevation, increasing nursing workload and potentially contributing to infection. This is especially relevant for patients with previously undiagnosed type 2 diabetes, which is not uncommon in Australian emergency practice. Glucose control must be managed without causing hypoglycaemia during transport or perioperative care.

Infection risk is another major concern. A patient with aspiration, pulmonary contusion, open fractures or prolonged ventilation may have limited physiological reserve. Corticosteroid-related immunosuppression can make pneumonia or wound infection more difficult to recognise and treat. Gastrointestinal bleeding and impaired tissue healing are less dramatic at the moment of prescribing, yet they may become clinically important days later.

The interpretation of evidence also deserves care. Observational studies can be distorted because healthier patients are more likely to receive timely treatment, while severely injured patients may be excluded or treated inconsistently. Trial participants may not resemble patients seen in contemporary trauma systems, where early CT, MRI, decompression and intensive care have improved. Benefit estimates from older studies therefore cannot be transferred uncritically to every modern patient.

A useful approach is to record the clinical reasoning in plain language: estimated injury time, neurological findings, contraindications, anticipated transfer duration, discussion with the spinal service and the agreed monitoring plan. Australian hospitals may use different electronic records and medication policies, but clear documentation protects continuity when care moves from a rural emergency department to a tertiary unit in Melbourne, Brisbane, Perth or Adelaide.

Shared decisions, consent and future research

When the patient is conscious and capable, the conversation should be direct. The clinician can explain that high-dose corticosteroids might offer a small chance of improved motor recovery when started early, but that the evidence is uncertain and serious complications are possible. In an unconscious patient, treatment may proceed under emergency principles when clinically justified, with family members informed as soon as practicable.

Communication should avoid presenting steroids as a proven way to “save the spinal cord”. Neurological outcome depends on the initial lesion, perfusion, decompression, rehabilitation, respiratory management and prevention of secondary complications. A patient who does not receive methylprednisolone has not necessarily missed the critical treatment. Early transfer, maintaining oxygenation and blood pressure, preventing hypothermia and delivering skilled intensive care may be more consequential.

Research priorities include better comparisons of steroid and non-steroid pathways in contemporary trauma systems, clearer patient-reported outcomes and more reliable data on subgroups. Future neuroprotective strategies may involve targeted anti-inflammatory agents, spinal cord perfusion optimisation or treatments tailored to injury biology. Any new therapy will need to demonstrate functional benefit, not simply a change in a neurological score.

The wider clinical conversation can benefit from disciplined online education. The professional background behind this resource is outlined in Dr Thamburaj’s profile, while broader medical discussions can help clinicians compare evidence without mistaking a single case report for a guideline. Even material outside spinal trauma, such as this syndromic surveillance example, illustrates how timing, data quality and context shape clinical interpretation.

For trainees and interested readers, case-based reflection is often more useful than memorising a protocol. A discussion of trigeminal neuralgia management is a reminder that treatment decisions in neurology frequently involve uncertain evidence, competing risks and the need to tailor care to the individual.

Clinicians managing acute spinal trauma should use current local policies, consult the receiving spinal or trauma service early and assess each patient rather than applying methylprednisolone automatically. Share a carefully reasoned case, review the latest evidence and take part in the professional discussion so that decisions about corticosteroids remain transparent, current and centred on meaningful neurological recovery.